Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × uridine triacetate × Gastrointestinal × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00044785 2005-06-24

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Wellstat Therapeutics

Phase 1 Terminated
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡